He Shoots And He Scores. Ardelyx (ARDX) Gains 78%. Happy New Year!
Ah yes, and Gains Come to the Patient, as the FDA Moves the Ardelyx Ball Further Along.
Despite the 78% gain since November 17th, the...
Ardelyx (ARDX). Don’t be Nervous, It’s Just Money.
The Higher it Goes, The More Nervous we Get.
LIVE QUOTE
Not much to report here, other then there could be news any day, any week....
Adding Unicycive (UNCY) $0.75 to the Watch List.
Similar to Ardlyx (ARDX) which we added to the Watch List last week, Unicycive (no we don't know how they pronounce it) which will call UNCY - is a biotech...
FDA Approval for Provention Bio (PRVB).
Re-cork the Champagne!
We were contemplating (dreaming) about an opening price over $12, and then a drift up towards $20, sometime during 2023. But no,...
Adding Ardelyx (ARDX) $1.57 to Watch List.
FDA Advisory Committee Says Go Forth Young Man!
While we hadn't previously owned Ardelyx, nor are they a client - there are a number of...
Provention Bio (PRVB) Announces $125 Million Term Loan Facility with Hercules Capital
Don't think we've ever seen anything like this before. Most investors who prefer to invest post FDA approval, invest post FDA approval. They got...
Adding Provention Bio (PRVB) $4.60 to 2022 Biotech Watch List.
This is in our 'Stocks we Hope to Double' Watch List.
LIVE QUOTE
Provention Bio (PRVB) Updates.
RELATED: Revive Therapeutics (RVVTF) Enters the Danger Zone.
Provention Bio...
Provention (PRVB) Price Target $18.
Headline Says Downgrade, But That's Near 300% Higher From Here!
LIVE QUOTE
Provention Bio (NASDAQ:PRVB) PT Lowered to $18.00 (MarketBeat).
July 7th: Provention Bio (NASDAQ:PRVB - Get Rating) had its...
Preventing Type I Diabetes. Here’s How Provention (PRVB) Works.
Here's How Provention's Treatment Works.
Interview With an Actual Provention Bio (PRVB) Clinical Trial Participant.
Conversation Between a Mikayla a Teenager who was at...
Teplizumab: Can We Delay the Onset of Type 1? (DiaTribe)
Teplizumab: Can We Delay the Onset of Type 1?
Last updated: 6/7/21
By Dr. Francine Kaufman
Provention Bio’s new injectable drug was recommended by an FDA committee...
Latest article
GeoVax (GOVX) Surges 51% on Massive Volume Spike.
MonkeyPox and Gedeptin Related News Spark New Investor Interest.
MARKET BRIEF
On a quiet Thursday afternoon, the 30th, while we were nearing completion of an updated...
Paving Past Obstacles on the Path to US Biosecurity
GeoVax’s CEO calls on government support to bolster domestic biotechnology and keep pace with China.
National biosecurity has become a frequent topic of conversation in...
Dinner Presentation With BioStem Technologies, Inc. (BSEM) in Boca Raton, FL
LIVE QUOTE
LONGER TERM CHART
Contact Ray Oliver at Bear Creek Capital for details.
RECENT NEWS
PRESENTATION
https://youtu.be/Au-pIqDHyto?si=_JKFAhwT-vvLSFqe
WOUND CARE REPORT
Global Wound Care Market to Reach USD 30.48 Billion by...
